Key result
AT/ET ratio >0.35 linked to ~154% higher mortality in high-gradient severe aortic stenosis.
Why the study?
No study had specifically assessed the prognostic impact of the acceleration time/ejection time ratio on outcome in patients with high-gradient severe aortic stenosis and no or mild symptoms.
Does an AT/ET ratio >0.35 predict increased all-cause mortality in patients with high-gradient severe aortic stenosis and preserved LVEF with no or mild symptoms?
Cohort (n=353)
Does an AT/ET ratio >0.35 predict increased all-cause mortality in patients with high-gradient severe aortic stenosis and preserved LVEF with no or mild symptoms?
An AT/ET ratio >0.35 is a strong predictor of all-cause mortality in patients with asymptomatic or mildly symptomatic high-gradient severe aortic stenosis, identifying a high-risk subgroup that may benefit from earlier intervention.
Answers are grounded in this paper and cite their sources.
AT/ET ratio >0.35 may flag higher-risk patients with high-gradient severe AS; leaves open need for prospective validation before guiding decisions.
Background The ratio of acceleration time/ejection time (AT/ET) is a simple and reproducible echocardiographic parameter that integrates aortic stenosis severity and its consequences on the left ventricle. No study has specifically assessed the prognostic impact of AT/ET on outcome in patients with high‐gradient severe aortic stenosis (SAS) and no or mild symptoms. We sought to evaluate the relationship between AT/ET and mortality and determine the best predictive AT/ET cutoff value in these patients. Methods and Results A total of 353 patients (median age, 79 years; 46% women) with high‐gradient (mean pressure gradient ≥40 mm Hg and/or aortic peak jet velocity ≥4 m/s) SAS, left ventricular ejection fraction ≥50%, and no or mild symptoms were studied. The impact of AT/ET ≤0.35 or >0.35 on all‐cause mortality was retrospectively studied. During a median follow‐up of 39 (25th–75th percentile, 23–62) months, 70 patients died. AT/ET >0.35 was associated with a considerable increased mortality risk after adjustment for established prognostic factors in SAS under medical and/or surgical management (adjusted hazard ratio [HR], 2.54; 95% CI, 1.47–4.37; P <0.001) or conservative management (adjusted HR, 3.29; 95% CI, 1.70–6.39; P <0.001). Moreover, AT/ET >0.35 improved the predictive performance of models including established risk factors in SAS with better global model fit, reclassification, and discrimination. After propensity matching, increased mortality risk persisted when AT/ET >0.35 (adjusted HR, 2.10; 95% CI, 1.12–3.90; P <0.001). Conclusions AT/ET >0.35 is a strong predictor of outcome in patients with SAS and no or only mild symptoms and identifies a subgroup of patients at higher risk of death who may derive benefit from earlier aortic valve replacement.
No takes yet. Share an insight, caveat, or question.
Altes et al. (2021) conducted a cohort in High-gradient severe aortic stenosis (n=353). AT/ET >0.35 vs. AT/ET ≤0.35 was evaluated on All-cause mortality (adjusted HR 2.54, 95% CI 1.47-4.37, p=<0.001). An AT/ET ratio >0.35 was associated with a increased risk of all-cause mortality in patients with high-gradient severe aortic stenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: